Bavarian Nordic A/S (BVNRY.PK), Thursday announced that the company could supply up to 13 million doses of its MVA-BN Mpox vaccine by the end of 2025, including 2 million doses in 2024.The Danish company added that it will be exploring additional options to expand its supply capacity for the vaccine, which is marketed under the names Jynneos, Imvamune and Imvanex.Bavarian Nordic has also identified another option to boost supply by 50 million doses over the next 12-18 months, subject to regulatory and market approvals.Currently, Bavarian Nordic's stock is trading at $11.70, up 0.86 percent on the OTC Markets.

巴伐利亚北欧公司周四宣布，到2025年底，该公司最多可供应1300万剂MVA-BN Mpox疫苗，其中包括2024年的200万剂。该丹麦公司补充称，将探索其他选择，以扩大该疫苗的供应能力，该疫苗以Jynneos、Imvamune和Imvanex的名义销售。巴伐利亚北欧公司还确定了另一种选择，在未来12-18个月内增加5000万剂的供应，但须经监管和市场批准。目前，巴伐利亚北欧的股价为11.70美元，在场外交易市场上涨0.86%。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股